Sugi Predict

Sugi Predict / Compounds / SCHEMBL1887152

SCHEMBL1887152

SCHEMBL1887152

CCOC(=O)c1cc(Br)cnc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK2 O96017 1/20 0.56
▸ TBK1 Q9UHD2 1/20 0.49
▸ KDM4E B2RXH2 6/20 0.49
▸ HSD17B10 Q99714 5/20 0.49
▸ ALDH1A1 P00352 5/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ OPRK1 P41145 1/20 0.48
▸ NPC1 O15118 4/20 0.47
▸ RAB9A P51151 4/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ TP53 P04637 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ HSP90AA1 P07900 1/20 0.47
▸ POLB P06746 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NFKB1 P19838 1/20 0.45
▸ NFKB2 Q00653 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31284004 1.00 CHEK2 (0.56) CHEK2TBK1KDM4EHSD17B10ALDH1A1
SCHEMBL15527494 0.84 OPRK1 (0.50) HSD17B10ALDH1A1MEN1KMT2AOPRK1
SCHEMBL5864153 0.84 OPRK1 (0.50) KDM4EHSD17B10ALDH1A1MEN1KMT2A
SCHEMBL912444 0.84 CHEK2 (0.59) CHEK2KDM4EHSD17B10ALDH1A1MEN1
SCHEMBL624362 0.84 CHEK2 (0.59) CHEK2KDM4EHSD17B10ALDH1A1MEN1
SCHEMBL10668140 0.83 OPRK1 (0.49) HSD17B10ALDH1A1MEN1KMT2AOPRK1
SCHEMBL28383608 0.83 CHEK2 (0.58) CHEK2KDM4EHSD17B10ALDH1A1MEN1
SCHEMBL29857790 0.82 OPRK1 (0.49) KDM4EALDH1A1KMT2AOPRK1TSHR
SCHEMBL1093551 0.82 OPRK1 (0.49) KDM4EALDH1A1KMT2AOPRK1TSHR
SCHEMBL18398582 0.81 OPRK1 (0.48) HSD17B10ALDH1A1MEN1KMT2AOPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104402881-B A kind of synthetic method of 3-aldehyde radical-6-bromine imidazo [1,2-a] pyridine-8-ethyl formate Dingyao County You Bang Chemical Co., Ltd. (CN) 2016-04-20 — — CN claimed
CN-104402881-A Synthetic method of ethyl 3-aldehyde-6-bromoimidazo[1,2-a]pyridine-8-formate DINGTAO COUNTY YOUBANG CHEMICAL INDUSTRY CO LTD 2015-03-11 — — CN claimed
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 — — US disclosed
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2024-11-21 — — US disclosed
EP-4308228-A1 PLASMA KALLIKREIN INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
CN-117396474-A Plasma kallikrein inhibitors 武田药品工业株式会社 2024-01-12 — — CN disclosed
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC 2023-07-13 — — US disclosed
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC 2023-07-13 — — US disclosed
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC 2023-07-13 — — US disclosed
US-11685736-B2 P2X3 and/or P2X2/3 compounds and methods ABS DEVELOPMENT 1, INC. (US) 2023-06-27 — — US disclosed
US-11685736-B2 P2X3 and/or P2X2/3 compounds and methods ABS DEVELOPMENT 1, INC. (US) 2023-06-27 — — US disclosed
US-20090156578-A1 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents DEBIOPHARM INTERNATIONAL SA (CH) 2009-06-18 — — US disclosed
CN-101415701-A Heterocyclylacrylamide compounds as FABI inhibitors and antibacterial agents AFFINIUM PHARM INC (CA) 2009-04-22 — — CN disclosed
EP-1973902-A2 3-HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS Affinium Pharmaceuticals, Inc. (CA) 2008-10-01 — — EP disclosed
WO-2007067416-A2 HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS AFFINIUM PHARMACEUTICALS, INC. (CA) 2007-06-14 — — WO disclosed
WO-2007067416-A2 HETEROCYCLYLACRYLAMIDE COMPOUNDS AS FABI INHIBITORS AND ANTIBACTERIAL AGENTS AFFINIUM PHARMACEUTICALS, INC. (CA) 2007-06-14 — — WO disclosed
EP-1585746-B1 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA LTD (GB) 2007-01-31 — — EP disclosed
US-20060069089-A1 Fungicides SYNGENTA CROP PROTECTION, INC. 2006-03-30 — — US disclosed
EP-1585746-A2 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS FUNGICIDES Syngenta Limited (GB) 2005-10-19 — — EP disclosed
WO-2004056824-A2 NAPHTHYRIDINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA LIMITED (GB) 2004-07-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156578-A1 3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents GAA, TFPI, DBI CHEK2 3206/4885TBK1 3191/4885KDM4E 3209/4885
US-20230219954-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS P2RX3, P2RX2, P2RX1 CHEK2 2654/4885TBK1 3273/4885KDM4E 1683/4885
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 CHEK2 1525/4885TBK1 3053/4885KDM4E 738/4885
US-20060069089-A1 Fungicides CBR3, TACR3, HCRTR1 CHEK2 3186/4885TBK1 4364/4885KDM4E 2175/4885
US-20240382482-A1 PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 CHEK2 1924/4885TBK1 3779/4885KDM4E 838/4885
US-11685736-B2 P2X3 and/or P2X2/3 compounds and methods P2RX3, P2RX2, P2RX1 CHEK2 2654/4885TBK1 3273/4885KDM4E 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.